Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson’s Disease | Zendy

Margherita Fabbri | Zendy; Sofia Reimão | Zendy; Miguel Carvalho | Zendy; Rita G. Nunes | Zendy; Daisy Abreu | Zendy; Leonor Correia Guedes | Zendy; Raquel Bouça | Zendy; Patrícia Pita Lobo | Zendy; Catarina Godinho | Zendy; Miguel Coelho | Zendy; Nilza Gonçalves | Zendy; Màrio Miguel Rosa | Zendy; Angelo Antonini | Zendy; Joaquim J. Ferreira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson’s Disease

Author(s) -

Margherita Fabbri,

Sofia Reimão,

Miguel Carvalho,

Rita G. Nunes,

Daisy Abreu,

Leonor Correia Guedes,

Raquel Bouça,

Patrícia Pita Lobo,

Catarina Godinho,

Miguel Coelho,

Nilza Gonçalves,

Màrio Miguel Rosa,

Angelo Antonini,

Joaquim J. Ferreira

Publication year - 2017

Publication title -

journal of parkinson s disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.747

H-Index - 45

eISSN - 1877-718X

pISSN - 1877-7171

DOI - 10.3233/jpd-171135

Subject(s) - neuromelanin , substantia nigra , parkinson's disease , magnetic resonance imaging , biomarker , disease , medicine , pathology , neurology , gastroenterology , nuclear medicine , neuroscience , psychology , chemistry , radiology , biochemistry

A specific T1-weighted magnetic resonance imaging (MRI) sequence has been shown to detect substantia nigra (SN) neuromelanin (NM) signal changes that accurately discriminate Parkinson's disease (PD) patients from controls, even in early disease stages. However, it is unclear what happens to these SN changes in later disease stages and if they can be a marker of disease progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research